TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06675955: An Open-label, Multicenter Extension Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Ocrelizumab in Patients With Multiple Sclerosis Previously Enro

Sponsor: Hoffmann-La Roche · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 500 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,600,440

Rescue Site Savings

+$9,641,800

Unlock Full NCT06675955 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06675955 Rescue Dossier →